Nishant Patel, MD
Cardiovascular Disease · Park Ridge, ILNPI 1194962225
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Novartis at 28.1% of the total. Reporting peaked in 2024 at $3,009 and has fallen 67.9% since, to $967 in 2025.
Across 147 payments — averaging $54.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Abbott$2K
- Boston Scientific$1K
- Abiomed$550
- Atricure, Inc.$248
- Johnson & Johnson$245
- plus $2K from 28 others
Across 38 payments — averaging $1440.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$55K
What the payments were for
- Consulting fees$2,18027%
- Travel & lodging$1,44018%
- Food & beverage$4,33254%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 4 | $2,237 |
| Abbott | 15 | $1,784 |
| Boston Scientific | 30 | $1,029 |
| Abiomed | 17 | $550 |
| Atricure, Inc. | 6 | $248 |
| Johnson & Johnson(2 entities) | 12 | $245 |
| Shockwave Medical, Inc | 2 | $229 |
| Edwards Lifesciences | 5 | $187 |
| Inari Medical, Inc. | 1 | $133 |
| Philips North America LLC | 4 | $107 |
| Biosense Webster, Inc. | 3 | $93 |
| Gentuity, LLC | 4 | $91 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $88 |
| Impulse Dynamics (USA) Inc. | 1 | $81 |
| Recor Medical Inc | 1 | $81 |
| Cardiva Medical, Inc. | 3 | $73 |
| Cordis US CORP. | 3 | $63 |
| Medtronic(2 entities) | 2 | $62 |
| AstraZeneca | 4 | $57 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $54 |
| Boehringer Ingelheim | 3 | $50 |
| Novo Nordisk | 2 | $45 |
| Heartflow, Inc. | 2 | $44 |
| Lexicon Pharmaceuticals, Inc. | 2 | $40 |
| ZOLL Circulation Inc | 1 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Terumo Medical Corporation | 2 | $35 |
| Teleflex LLC | 2 | $32 |
| Pfizer | 2 | $32 |
| Biotronik Inc. | 2 | $25 |
| Cook Medical LLC | 1 | $23 |
| Lilly USA, LLC | 1 | $20 |
| Getinge USA Sales, LLC | 1 | $19 |
| EKOS Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIS$1,182
- XIENCE SIERRA$190
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$155
- OptiCross 6$146
- AVVIGO Guidance System$141
- Impella$139
- FlowTriever$133
- ClotTriever$133
- Xience V coronary stent system$120
- SYNERGY ABLATION SYSTEM$120
- GENERAL - STENTS$115
How this compares
$7,951 in reported general payments places this provider in the 80th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 321 | $407,114 |
| EntrestoSacubitril/Valsartan | 143 | $158,949 |
| XareltoRivaroxaban | 74 | $89,500 |
| JardianceEmpagliflozin | 45 | $38,892 |
| Repatha SureclickEvolocumab | 15 | $22,519 |
| BrilintaTicagrelor | 22 | $14,882 |
| FarxigaDapagliflozin Propanediol | 13 | $14,237 |
| VascepaIcosapent Ethyl | 35 | $8,757 |
| Metoprolol Succinate | 588 | $8,701 |
| Atorvastatin Calcium | 687 | $7,810 |
| TradjentaLinagliptin | 11 | $5,108 |
| Amlodipine Besylate | 489 | $3,939 |
| Losartan Potassium | 344 | $3,764 |
| Rosuvastatin Calcium | 283 | $3,761 |
| Bumetanide | 114 | $3,603 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $32 | $407,114321 claims |
| NovartisEntresto | $2,237 | $158,949143 claims |
| Johnson & JohnsonXarelto | $245 | $89,50074 claims |
| Boehringer IngelheimJardiance, Tradjenta | $50 | $44,00156 claims |
| AstraZenecaBrilinta, Farxiga | $57 | $29,11935 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Park Ridge
- Sandeep NathanChicago$892K
- Alan BrownNaperville$858K
- Azmey MatariehElgin$762K
- Jay AlexanderBannockburn$744K
- Niraj VarmaMaywood$522K
- Boaz AvitallChicago$366K
- Akhil NarangChicago$363K
- Mark RabbatMaywood$363K
- Michael DavidsonChicago$317K
- Robert KochLibertyville$298K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.